Gilead Chairman and CEO Daniel ODay called Livdelzi an important new option for patients and doctors, adding, People living with PBC [primary biliary cholangitis] have been waiting for treatment advancements for many years. Livdelzis approval is supported by the Phase III RESPONSE trial, in which treatment with the drug elicited a significantly higher rate of composite biochemical response
Simply reorder when youre ready
10.1210/en.2017-00349 55 HolscherC
GLP-1RA or dual GIP/GLP-1RA added to basal insulin compared to basal insulin titrated with a rigorous intention-to-treat approach is moderately effective in preventing further increase in daily basal insulin dose from achieving treat-to-target glycemic goals ( daily insulin dose, SMD -0.49, 95% CI -0.71
Radiation-induced bystander signaling pathways in human fibroblasts: a role for interleukin-33 in the signal transmission
$173/mo vs ~$1,1001,400/mo projected brand price about 86% less